A phase 1 clinical trial of a new cellular immunotherapy being developed in Australia for the treatment of multiple sclerosis (MS) has found that it improved symptoms and quality of life for the majority of patients.

Latest Video
New Stories
-
New leadership for Mundipharma ANZ with Jane Orr announcing retirement
December 6, 2019 - - Latest News -
AusBiotech 'astonished' after R&D tax cut legislation tabled on final day
December 6, 2019 - - Latest News -
GSK welcomes new approvals for asthma biologic
December 6, 2019 - - Latest News -
NZ to fund AZ's ovarian cancer therapy, finally
December 6, 2019 - - Latest News -
New patient alliance calls for independent review of HTA
December 5, 2019 - - Latest News -
Artificial intelligence to feature at BioPharmaDispatch 2020
December 5, 2019 - - Latest News -
CSL highlights pipeline at investor briefing
December 5, 2019 - - Latest News